{"entity":{"id":"novartis","kind":"company","name":"Novartis","aka":["Endocyte"],"tldr":"The company that made radioligand therapy a business, with Pluvicto and Lutathera, and the maker of Kisqali and Gleevec.","summary":"Novartis, based in Basel and listed as NOVN.SW, is the company that made radioligand therapy a business with Pluvicto and Lutathera, and the maker of Kisqali, Gleevec, Scemblix and Kymriah, the first approved CAR-T. Pluvicto sells more than 1.5 billion dollars a year, and the pipeline includes actinium-225 PSMA-617, FAP-2286 and the Mariana Oncology acquisition, alongside adjuvant ribociclib, imatinib and asciminib. Nuclide links it to the first imatinib trial and IRIS, to ELIANA and JULIET for tisagenlecleucel, to peptide receptor radionuclide therapy, to the AlphaBreak and AcTION actinium trials, and to ideas on Western ytterbium-176 enrichment and two-day CAR-T manufacture. Manufacturing cost and time for living and radioactive medicines is the bottleneck its two flagship modalities share. Lutetium-177 vipivotide tetraxetan and lutetium-177 dotatate have their own pages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Novartis","links":[{"label":"Official website","url":"https://www.novartis.com"}],"tags":[],"related":["lu-177","ac-225"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":["pluvicto","lutathera","ac225-psma","fap-2286","aaa817"],"companies":["mariana-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["netter-1","nct05939414","nct04711135","nct06894511","nct06004661","nct05142696"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel","country":"CH","companyType":"pharma","website":"https://www.novartis.com","ticker":"NOVN.SW","investors":[],"funding":[]},"route":"/companies/novartis/","neighbours":{"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"drug":[{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/"},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/"},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/"},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"},{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/"}],"trial":[{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/"},{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/"},{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/"},{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/"},{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/"},{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/"},{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/"},{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/"},{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/"}],"indication":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/"},{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/"}],"institution":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/"}],"idea":[{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/"}],"bottleneck":[{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/"},{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/"},{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/"}],"paper":[{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}],"section":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/"},{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/"}],"roadmap":[{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/"}]}}